Literature DB >> 29125477

MicroRNA-186 suppresses lung cancer progression by targeting SIRT6.

Libo Ruan1,2,3, Jun Chen2, Litao Ruan4, Tianrui Yang2, Ping Wang1,3,5.   

Abstract

MicroRNAs are a class of small non-coding RNA molecules that play crucial roles in the initiation and progression of lung cancer. This study was undertaken to investigate the expression and roles of miR-186 in lung cancer. Ectopic expression experiments demonstrated that miR-186 functions as a tumor suppressor. Bioinformatic predictions, a luciferase reporter assay, and protein expression analysis suggested that miR-186 could inhibit the protein levels of SIRT6, a purported tumor suppressor gene. Collectively, our results indicated that miR-186 could inhibit lung cancer progression through targeting SIRT6 and that miR-186 may be a therapeutic target for lung cancer.

Entities:  

Keywords:  Lung cancer; SIRT6; apoptosis; miR-186; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29125477     DOI: 10.3233/CBM-170650

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  11 in total

1.  Age-related epigenetic drift deregulates SIRT6 expression and affects its downstream genes in human peripheral blood mononuclear cells.

Authors:  Magdalena Owczarz; Jacek Połosak; Anna Domaszewska-Szostek; Paulina Kołodziej; Alina Kuryłowicz; Monika Puzianowska-Kuźnicka
Journal:  Epigenetics       Date:  2020-06-23       Impact factor: 4.528

Review 2.  Association of sirtuins (SIRT1-7) with lung and intestinal diseases.

Authors:  Yuhan Chen; Di Zhou; Yuan Feng; Bingxin Li; Yong Cui; Gang Chen; Ning Li
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

Review 3.  Emerging roles of SIRT6 in human diseases and its modulators.

Authors:  Gang Liu; Haiying Chen; Hua Liu; Wenbo Zhang; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-16       Impact factor: 12.944

Review 4.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

5.  MiR-186 Suppressed Growth, Migration, and Invasion of Lung Adenocarcinoma Cells via Targeting Dicer1.

Authors:  Juan Wang; Yi Zhang; Fanghong Ge
Journal:  J Oncol       Date:  2021-11-11       Impact factor: 4.375

6.  SIRT6 Promotes the Progression of Prostate Cancer via Regulating the Wnt/β-Catenin Signaling Pathway.

Authors:  Xian Zhang; Rong Chen; Li-De Song; Ling-Fei Zhu; Jian-Fei Zhan
Journal:  J Oncol       Date:  2022-02-25       Impact factor: 4.375

7.  MiR-186-3p attenuates tumorigenesis of cervical cancer by targeting IGF1.

Authors:  Xiurong Lu; Xiao Song; Xiaohui Hao; Xiaoyu Liu; Xianyu Zhang; Na Yuan; Huan Ma; Zhilin Zhang
Journal:  World J Surg Oncol       Date:  2021-07-12       Impact factor: 2.754

8.  Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.

Authors:  Carlos Pedraz-Valdunciel; Stavros Giannoukakos; Nicolas Potie; Ana Giménez-Capitán; Chung-Ying Huang; Michael Hackenberg; Alberto Fernandez-Hilario; Jill Bracht; Martyna Filipska; Erika Aldeguer; Sonia Rodríguez; Trever G Bivona; Sarah Warren; Cristina Aguado; Masaoki Ito; Andrés Aguilar-Hernández; Miguel Angel Molina-Vila; Rafael Rosell
Journal:  Mol Oncol       Date:  2022-02-10       Impact factor: 7.449

Review 9.  The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA.

Authors:  Ying Xiang; Qing Tian; Li Guan; Shuai-Shuai Niu
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

10.  Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer.

Authors:  Haiqin Xie; Jinliang Chen; Xuedong Lv; Lu Zhang; Jinnan Wu; Xin Ge; Qichang Yang; Dongmei Zhang; Jianrong Chen
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.